Редкие формы рака тела матки: клиническое течение и факторы прогноза
Диссертация
Е-кадхерин является прогностически наиболее значимым иммуногистохимическим маркером среди молекул межклеточной адгезии при редких формах рака тела матки. Для него получены самые высокие коэффициенты корреляции (р<0,01,) и веса в многофакторной модели. Пяти-и 10 — летняя общая и безрецидивная выживаемость у пациенток редкими формами рака тела матки коррелирует с нарушением экспрессии молекул… Читать ещё >
Содержание
- Глава I. Обзор литературы
- Глава II. Материал и методы
- Глава III. Клинико-морфологическая характеристика редких форм рака тела матки, особенности течения и варианты лечения
- ГЛАВА IV. Лечение пациенток редкими формами рака тела матки
- ГЛАВА V. Рецидивы и метастазы у пациенток редкими формами рака тела матки
- ГЛАВА VI. Иммуногистохимическое исследование молекул межклеточной адгезии и рецептора эпидермального фактора роста у пациенток редкими формами рака тела матки
- ГЛАВА V. n. Анализ выживаемости пациенток редкими формами рака тела матки
- ГЛАВА VI. H. Многофакторный анализ прогноза возврата болезни у пациенток редкими формами рака тела матки
Список литературы
- Авдеев В. И. Клиническое значение изучения гормонального статуса и рецепторов стероидных гормонов, в опухоли у больных раком эндометрия: Авторефер. дис. канд. мед. наук. —М., 1987. — С. 15—25.
- БохманЯ.В. Руководство по онкогинекологии.— Л.: Медицина. 1989. —С. 275—340.
- Васильева Е.В., Белианин B.JL: Серозная аденокарцинома: критерии морфологического диагноза и иммуногистохимия// Архив патологии, 2005- 67(2): 25−7.
- ДильманВ. М. Эндокринологическая онкология.— JL: Медицина. 1983. —С. 121—136.
- Е.А.Ульрих, Э. Л. Нейштадт. Редкие формы рака тела матки. Практическая Онкология Т. 5, № 1 — 2004.
- Мартынов С. Я. Минимальный рак эндометрия. — С-Пб.: Гиппократ, 1994. —С. 94.
- Нечушкина В.М., Богатырев В. Н., Кузнецов В. В. и соавт. Клинико-морфологические факторы прогноза и параметры клеточного цикла при раке тела матки// Вестник РОНЦ им. H.H. Блохина РАМН, 2006- т.17, № 1, стр. 3741.
- Пожарисский K.M., Леенман Е. Е. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний// Архив патологии, 2000, № 5, 3−11.
- Пожарисский K.M., Самсонова Е. А., Тен В.П. и соавт.: Иммуногистохимический профиль эндометриоидной аденокарциномы тела матки: ER, PR, Her-2, Ki-67 и их прогностическое значение//Архив патологии, 2005, № 2, С.13−17.
- Ткачева Н. Ю. Рецепторы прогестерона в матке в норме и при опухолевом росте: Авторефер. дис. канд. мед. наук. — М., 1994. — 35 с.
- Ульрих Е. А., Нейштадт Э.Л, Зельдович Д. Р, Урмачеева А. Ф. Комплексное лечение больных серозно-папиллярным раком/ Материалынауч.-практ. конф. Посвящ. 85-летию со дня основания ЦНИРРИ МЗ РФ. — СПб., 2003. с.233−234.
- Урманчеева А.Ф., Ульрих Е. А., Нейштадт Э. Л., Зельдович Д. Р., Дикарева А. В. Серозно-папиллярный рак эндометрия (клинико-морфологические особенности// Вопр. Онкол. — 2002. — Т.48, № 6. — С. 679 683.
- Харитонова Т.В. Рак тела матки// Современная онкология. — 2000. — Т. 2, № 2. —С. 4—10.
- Чернобровкина А. Е. Клинико-патогенетическое значение содержания эстрогенов в ткани рака эндометрия: Дис. канд. мед. наук.— М., 1999.— 112 с.
- Aalders I, Abeler V., Kolstad P., et al.: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 1980- 56: 419−427.
- Abeler V.M., Vergote I.B., Kjorstad K.E. et al.: Clear-cell carcinoma of the endometrium. Prognostic and metastatic pattern // Cancer. 1996. Vol. 78. — P. 1740−1747.
- Alektiar V.M., McKee A., Lin O. et al.: Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?// Int J Radiat Oncol Biol Phys, 2002 54: 7985.
- Alkuchi A., Lim P., Coldman A. et al.: Interpretation of p53 imimmoreactivity in endometrial carcinoma: establishing a clinically relevant cutoff level// Int J Gynecol Pathol. 2004- 23(2): 129−37.
- Anastasiadis P.Z., Reynolds A.B.: The pl20 catenin family: complex roles in adhesion, signaling and cancer// J Cell Sci. 2000 Apr- 113 (Pt 8):1319−34.
- Athanassiadou P, Athanassiades P., Grapsa D. et al. The prognostic value of PTEN, p53 and P-catenin in endometrial carcinoma: a prospective immunocytochemical study// Int Gynecol Cancer 2007, 697−704.
- Bancher-Todesca T.D., Neunteufel W., Williams K.E., et al. Influens of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecologic Oncology 1998- 71: 344−347.
- Bedwinek J., Galakatos A., Camel M., et al.: Stage I, grade IE adenocarcinoma of the endometrium treated with surgery and irradiation. Sites of failure and correlation of failure rate with irradiation technique// Cancer. 1984- 54(l):40−7.
- Boruta D.M. 2nd, Gehrig P.A., Groben P.A., Bae-Jump V., et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?// Cancer, 2004, 101: 2214−2221.
- Bremnes R.M., Veve R., Hirsch F.R. et al.: The E-cadherin cell-cell adhesion complex and cancer invasion, metastasis, and prognosis//Lung Cancer. 2002- 36(2): 115−24.
- Burke T.W., Gershenson D.M., Morris M., et al.: Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma// Gynecol Oncol. 1994- 55(l):47−50.
- Calais G., Vitu L., Descamps P., Body G., et al.: Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II// Int J Radiat Oncol Biol Phys. 1990 -19(3):523−7.
- Cantero D., Friess H., Deflorin J., et al.: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma// Br J Cancer. 1997- 75(3):388−95.
- Carcangiu M.L., Cambers J.T. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival // Int J Gynecol Pathol. 14(l):30−8- 1995.
- Chan J.K., Lozzi V., Youssef M., et al.: Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium// Gynecol Oncol, 2003 90: 181−185.
- Christman E., Kapp D., Hendrickson M, et al.: Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report. Gynecol Oncol 26:228 235, 1987.
- Cirisano F.D., Robboy S.J., Dodge R.K. et al. The outcome of stage I—II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma//Gynecol Oncol, 2000, 77, 55−65.
- Clement P. B, Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 11: 117−142- 2004.
- Coronado P.J., Vidart J.A., Lopez-asenjo J.A. et al.: P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression// Eur J Obstet Gynecol Reprod Biol. 2001- 98(1): 103−8.
- Cowles T. A. Magrina J. F., Masterson B. J. Comparison of clinical and surgical staging in patients with endometrial carcinoma//Obstet Gynecol 1985, Vol. 66, № 3: 413—416.
- Craighead P. S., Sait K., Gavin C.S. et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994// Gynecol Oncol 77, 248−253 (2000).
- Creasman W.T., Kohler M.F., Odicino F., et al.: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium// Gynecol Oncol 2004- 95: 593−596.
- Creasman W.T., Morrow C.P., Bundy B.N., et al: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study// Cancer 1987 Oct 15- 60(8 Suppl):2035−41.
- Creasman W. T., Soper J. T., McCarty K. S., Jr. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma//Am. J. Obstet. Gynecol. — 1991. — Vol. 151, № 7. — P. 922—932.
- Dallenbach-Hellweg G., Hahn U.: Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens// Int J Gynecol Patol. 1995- 14:7−15.
- Eifel P.J., Ross J., Hendrickson M., et al: Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons//Cancer. 1983- 52(6): 1026−31
- Frank A.H., Tseng P.C., Haffty B.G., et al.: Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma// Cancer 1991- 68(7): 15 169.
- Gallion H.H., Van Nagell J.R. Koborn E.I. et al.: Stage I papillary carcinoma of endometrium// Cancer. 1989. — Vol. 63. — P. 2224−2228.
- Geisinger K. R., Homesley H. D., Morgan T. M. Endometrial adenocarcinoma: a multiparameter clinicopathologic analysis including the DNA profile and sex hormone receptors//Cancer. — 1986. — Vol. 58, '7. — P. 1518— 1525.
- Geisler J.P., Geisler H.E., Melton M.E., et al: What staging surgery should be performed on patients with uterine papillary serous carcinoma// Gynecol Oncol 1998- 69: 69−73.
- Geisler JiP., Geisler H.E., Wiemann M.C., et al.: P53 expression as a prognostic indicator of 5-year survival in endometrial cancer// Gynecol Oncol. 1999- 74(3): 468−71.
- Genest P., Drouin P., Girard A., Gerig L.: Stage III carcinoma of the endometrium: a review of 41 cases// Gynecol Oncol. 1987- 26(l):77−86.
- Gibbons S., Martinez A., Schray M., et al: Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma// Int J Radiat Oncol Biol Phys. 1991- 21(4):1019−25.
- Goff B.A., Kato D., Schmidt R.A., et al.: Uterine papillary serous carcinoma: Patterns of metastatic spread // Gynecol Oncol 1994- 554:264−268.
- Grant P.T., Jeffrey J.F., Fraser R.C., et al: Pelvic radiation therapy for gynecologic malignancy in geriatric patients// Gynecol Oncol 1989- 33(2):185−8.
- Greer B.E., Hamberger A.D.: Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation// Gynecol Oncol 1983−16(3):365−73.
- Greven K.M., Lanciano R.M., Corn B., et al.: Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. // Cancer. 1993- 71(11): 3697−702.
- Greven K.M., Randall M., Fanning J., et al: Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium//Int J Radiat Oncol Biol Phys. 1990−19(3):529−34.
- Grice J., Ek M., Greer B., et al: Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998, 69: 69−73.
- Grigsby P.W., Perez C.A., Kuske RR., et al.: Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium// Gynecol Oncol. 1987- 27(l):44−57.
- Grigsby P.W., Perez C.A., Camel H.M., et al.: Stage II carcinoma of the endometrium: results of therapy and prognostic factors// Int J Radiat Oncol Biol Phys. 1985- 1 l (ll):1915−23.
- Halperin R., Zebavi S., Habler L. et al.: Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium // Europ. J. Gynecol.Oncol. 2001. — Vol.22 (2). — P. 122−126.
- Hamilton C.A., Cheung M.K., Osann K. et al.: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers//British Journal of Cancer (2006) 94, 642−646.
- Hendrickson M., Longacre T.A.& Kempson R.L. Uterine papillary serous carcinoma revisited. Editorial. Gynecol Oncol 1994- 54: 261−263.
- Hendrickson M., Ross J., Eifel P. et al.: Uterine papillary carcinoma: a highly malignant from of endometrial adenocarcinoma // Amer. J. Surg. Pathol. 1982.-Vol. 6 (2).-P. 93−108.
- Hendrickson M., Ross J., Eifel P.J.: Adenocarcinoma of the endometium: analysis of 256 cases with carcinoma limited to the uterine corpus// Gynecol Oncol 13:373−392, 1982.
- Hoffman K., Nekhlyudov L., Deligdisch L., et al: Endometrial carcinoma in elderly women// Gynecol Oncol 1995- 58(2):198−201.
- Huh W.K., Powell M., Leath III CA, et al.: Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy// Gynecol Oncol, 2003, 91: 470−475.
- Inaba F., Kawamata H., Teramoto T. et al.: PTEN and p53 abnormalities are indicative and predicative factors for endometrial carcinoma// Oncol Rep. 2005- 13(l):17−24.
- Jawhari A., Jordan S., Poole S. et al.: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival// Gastrointerology. 1997- 112 (1): 46−54.
- Kadar N., Malfetano J.H., Homesley H.D.: Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy// Obstet Gynecol. 1992- 80(4):655−9.
- Karahan N., Guney M., Baspinar S. et al.: Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma// Eur J. Gynecol Oncol. 2007, 28(3): 184−8.
- Kataoka A., Nishida T., Sugiyama T., et al.: Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation// Gynecol Oncol. 1997- 65:180−184
- Kato D.T., Ferry J.A., Goodman A. et al.: Uterine papillary serous carcinoma (UPSC): A clinicopathologic study of 30 cases. Gynecol Oncol 1995- 59 (3): 384−389.
- Kauppila A. Estrogen and progestin receptors as prognostic in endometrial cancer//Acta. Oncol. — 1989. — Vol. 28, № 4. — P. 561—566.
- Khalifa M.A., Mannel R.S., Haraway S.D. et al. Expression of EGFR, Her-2/neu, P53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas//Gynecologic Oncology 1994: 53, 84−92.
- Kim Y.T., Choi E.K., Kim J.W. et al.: Expression of E-cadherin and ?-, 0-, y- catenin proteins in endometrial carcinoma//Yonsei Med J 43:701−711, 2002.
- Klapper L.N., Waterman H., Sela M.: Tumor-inhibitory antibodies to Her2/ErbB2 may act by recruiting c-Clb and enhancing ubiquitination of Her-2// Cancer Res. 2000- 60(13): 3384−8.
- Kounelis S., Kapranos N., Kouri E. et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Copyriht © 2000 by The United States and Canadian Academy of Pathology, Inc. Vol.13, NO. 4, P. 379.
- Kurman R.J., Scully R.E. Clear cell carcinoma of the endometrium: an analysis of 21 cases. // Cancer 1976, 37 (2): 872−82.
- Lanciano R.M., Curran W.J., Greven K.M., et al: Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium// Gynecol Oncol. 1991- 40: 368−73.
- Lauchlan SC: Tubal (serous) carcinoma of the endometrium. Arch Patrol Lab Med 105:615−618, 1981.
- Lax S.F., Pizer E.S., Ronnett B.M., et al.: Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression// Hum Pathol. 1998- 29(6):551−8.
- Levenback C., Burke T.W., Silva E., et al. Uterine papillary serous carcinoma treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)// Gynecol Oncol 1992- 46: 317−321.
- LiaoB. S., Twiggs L. B., Leung B. S. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma//Obstet. Gynecol. — 1986. — Vol. 67, № 4. — P. 463-^167.
- Lim P., Al Kushi A, Gilks B., et al.: Early stage uterine papillary serous carcinoma of the endometrium// Cancer. 2001- 91:752−757.
- Loeffler J.S., Rosen E.M., Niloff J.M., et al: Whole abdominal irradiation for tumors of the uterine corpus// Cancer 1988- 61(7):1332−5.
- Lynch C.C., Matrisian L.M.: Matrix metalloproteinases in tumor-host cell communication//Differentiation. 2002- 70 (9−10): 561−73.
- Mackillop W.J., Pringle J.F.: Stage III endometrial carcinoma. A review of 90 cases// Cancer 1985- 56(10):2519−23.
- Mallipeddi P., Kapp D.S. & Teng N.N. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma// Cancer 1993−71:3076−3081.
- Malpica A., Tornos C., Burke T.W., et al: Low-stage clear-cell carcinoma of the endometrium// Am J Surg Pathol. 1995- 19(7):769−74.
- Marchetti D.L., Caglar H., Driscoll D.L., et al: Pelvic radiation in stage I endometrial adenocarcinoma with high-risk attributes// Gynecol Oncol 1990- 37(l):51−4.
- Martin J. D., HahnelR., McCartney A. J. The effect of estrogen receptor status on survival in patients with endometrial cancer//Am. J. Obstet. Gynecol. — 1993. — Vol. 147, № 3. — P. 322—324.
- Martinez A., Schary M., Podratz K., et al: Prospective whole abdominopelvic irradiation for patients with high risk endometrial cancer// Int J Radiat Oncol BiolPhys. 1989- 17:371−377.
- Matsui S., Shiozaki H., Inoue M. et al.: Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer// Virchows Arch. 1994- 424(4): 375−81.
- Matthews R.P., Hutchinson-Colas J., Maiman M. et al.: Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women// Gynecologic Oncology 65, 206−212 (1997).
- Mayr N.A., Wen B.C., Benda J.A., et al: Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement—patterns of failure//Radiology 1995- 196(2): 323−8.
- Mell L.K., Meyer J.J., Tretiakova M. et al.: Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer// Clin Cancer Res 2004- 10: 5546−553.
- Memarzadeh S., Kozak K. R., Chang L. et al.: Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer// Proc Natl Acad Sci USA. 2002- 99 (16): 10 647−52.
- Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of endometrium: A Gynecology Oncology Group study. Gynecol Oncol 1991- 40:55−65.
- Murphy K.T., Rotmensch J., Yamada S.D., et al: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy//Int J Radiat Oncol Biol Phys. 2003- 55(5): 1272−6.
- Mutter G.L.: Pten, a protean tumor suppressor// Am J Pathol. 2001- 158(6): 1895−8.
- Nicklin J.L. & Copeland L.J., Endometrial papillary serous carcinoma: patterns of spread and treatment// Clinical Obstetrics and Gynecology 1996- 39: 686:695.
- Novak E. Gynecological and Obstetrical Pathology. — Philadelphia: W.B. Sanders, 1947. P. 225−241
- Nyholm H., Christensen IJ, Nielsen AL. Den prognostics betydning of progesteron receptoring hold ved endometrial cancer//Ugeskr. Laeger. — 1997. — Vol. 159, № 5.P. 601—604.
- Oreskovic S., Babic D., Kalafatic D. et al.: A significance of immunohistochemical detennination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma// Gynecol Oncol. 2004- 93(1): 34−40.
- Osmanagaoglu M.A., Kadioglu S., Osmanagaoglu S. et al.: The relationship between mutant p53gene, DNA contents and conventional clinicopatological prognostic variables in cases with endometrial carcinoma// Eur J Gynecol Oncol. 2005- 26 (1): 64−70.
- Palmer D. C., Muirl. M., Alexander A. I. The prognostic importance of steroid receptors in endometrial carcinoma//Obstet. Gynecol. — 1998. — Vol. 72, № 3. p. 388—393.
- Potish R.A., Twiggs L.B., Adcock L.L., et al: Role of whole abdominal radiation therapy in the management of endometrial cancer- prognostic importance of factors indicating peritoneal metastases// Gynecol Oncol 1985 May-21(l):80−6.
- Pradhan M., Abeler V.M., Danielsen H.E. et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas// Mod Pathol. 2006- 19(9): 1227−35. Epub.
- Price F.V., Chambers S.K., Carcangiu M.L., et al. Intravenous cisplatin, doxorubicin, and cyclophosphamide in treatment of uterine papillary serous carcinoma// Gynecol Oncol 1993- 51: 383−389.
- Price F.V., Edwards R.P., Kelley J.L., et al: A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report// Semin Oncol. 1997- 24(5 Suppl 15):S15−78-S15−82.
- Randall M.E., Wilder J., Greven K., et al: Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma// Int J Radiat Oncol Biol Phys. 1990- 19(l):49−54.
- RiceL. W., JazaeriA. A., ShupnikM. A. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma//Gynecol. Oncol. — 1997. — Vol. 65, № 1. — P. 149—157.
- Rodolakis A., Papaspyrou I., Sotiropoulou M. et al.: Primary squamous cell carcinoma of the endometrium. A report of 3 caseses// Eur. O. Gynaecol. Oncol. 22: 143−146, 2001.
- Rosenberg P., Boeryd B. & Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer// Gynecol Oncol 1993- 48: 32−37.
- Ross J.C., Eifel P.J., Cox R.S. et al.: Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study // Amer. J. Surg. Pathol. 1983. — Vol.7. — P. 715−729.
- Saegusa M., Hashimura M., Kuwata T., et al.: Beta-catenin simultaneously induces activation of the p53-p21WAFl pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells// Am J Pathol. 2004- 164(5): 1739−49.
- Sakuragi N., Nishiya M., Ikeda K., et al.: Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion//Gynecol Oncol 1994- 53 (2): 183−189.
- Santin A.D., Bellone S., Gokden M, et al.: Overexpression of Her-2/neu in uterine serous papillary cancer// Clin Cancer Res 2002- 8:1271−9.
- Schlosshauer P.W., Ellenson L.N., Soslow R.A.: Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype// Mod Pathol. 2002- 15(10): 1032−7.
- Scully R.E., Barlow J.F. Mesonephroma of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma// Cancer. 1967. — Vol. 20. — P. 1405−1417.
- Sherman M.E., Bitterman P., Rosenbein N.B. et al.: Uterine papillary carcinoma. A morphologically disease neoplasm with unifying clinicopathologic features// Amer. J. Surg. Pathol. 1992. — Vol. 16 (6). P. 600−610.
- Shidara Y. Karube A., Watanabe M. et al.: A case report: verrucous carcinoma of the endometrium — the difficalty of diagnosis and a review of the literature//J. Obstet Gynaecol Res -2000.- 26: 189−192.
- Silverberg S., Kurman R. Tumours of the uterine corpus and gestational trophoblastic disease// Armed forces institute of paphology. 1992. — Atlas of tumor pathology. Third Series. — Fascicle 3. — D.C. Washington. P. 240−288.
- Slomovitz B.M., Burke T.W., Eifel P.J. et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases// Gynecol Oncol. 2003- 91(3): 463−469.
- Slomovitz B.M., Russell B.R., Burke T.W. et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma// Clinical Oncology 2004- Vol. 22, № 15- 3126−3132.
- Small W., Mahadevan A., Roland P., et al: Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival// Cancer J. 2000- 6(6):394−400.
- Smith R.S., Kapp D.S., Chen Q., et al.: Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy// Int J Radiat Oncol Biol Phys. 2000 Oct l-48(3):767−78.
- Smith R.S., Peters W.A., Drescher C.W.: Cisplatin, doxorubicin hydrochloride and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma// Am J Obstet Gynecol 1994- 170:1677−1682.
- Stefansson I.M., Salvensen H.B., Akslen L.A. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers inendometrial cancer// J Clin Oncol 22:1242−1252. © 2004 by American Society of Clinical Oncology.
- Susini T., Amunni G., Molino C. et al.: Ten-years results of prospective study on the prognostic role of ploidy in endometrial carcinoma// Cancer 2007 — Vol.109, № 5-P. 882−890.
- Talvensaari-Mattila A, Santala M, Soini Y, et al: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma//Anticancer Res. 2005- 25(6B):4101−5.
- Tecimer C., Doering D.L., Coldsmith L.J. et al.: Clinical relevance of urokinase-type plasmogen activator, its receptor, and its inhibitor type 1 in endometrial cancer// Gynecol Oncol. 2001- 80(1): 48−55.
- Trope C., Kristensen G.B., Abeler V.M.: Clear-cell and papillary serous cancer: treatment options// Baillieres. Best Practice & Research Clinical Obstetrics and Gynecology Vol. 15, No. 3, pp 433−446, 2001.
- Vasil’eva E.V., Belianin V.L.: Serous adenocarcinoma of uterus: criteria of morphological diagnosis and immunohistochemistry// Arkh Patol. 2005- 67(2): 25
- Wheeler D.T., Bell K.A., Kurman R.J. et al.: Minimal uterine serous carcinoma// Am. J. Surg. Pathol. 2000- 24:797−806.
- Wijnhoven B.P., Dinjens W.N., Pignatelli M.: E-cadherin-catenin cell-cell adhesion complex and human cancer// Br J Surg. 2000- 87(8): 992−1005.1
- Wu H., Goel V., Haluska F.G.: PTEN signaling pathways in melanoma// Oncogene. 2003- 22(20):3113−22.
- Xing R.H., Rabbani S.A.: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis// Int J Cancer. 1996- 67(3):423−9.
- Yoon S.O., Park S.J., Yun C.H., et al.: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis// J Biochem Mol Biol. 2003- 36(1): 128−37. Review.
- Yu D., Hung M.C.: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies //Oncogene. 2000. — Vol.19. — P.6115−6121.
- ZainoR. J., Satyaswaroop P. G., MortelR. The relationship of histologic and histochemical parameters to progesterone receptor status in endometrial adenocarcinomas//Gynecol. Oncol. — 1992. — Vol. 16, № 2. — P. 196—208.
- Zanotti K.M., Belinson J.L., Kennedy A.W., et al.: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma// Gynecol Oncol 1999- 74(2):272−7.